Renin‐angiotensin system inhibition vs supportive treatment
Death · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
275 questions · 279 findings · 32 reviews · Kidney and Transplant
No studies found 76 · 27.2%GRADE not reported 5 · 1.8%Very low 42 · 15.1%Low 105 · 37.6%Moderate 46 · 16.5%High 5 · 1.8%
Renin‐angiotensin system inhibition vs supportive treatment
Kidney failure · people IgA nephropathy
It is very uncertain whether renin‐angiotensin system inhibition changes kidney failure compared with other supportive care treatment (very low certainty).
1 finding from 1 review
- RR 0.2 [0.01, 3.88]1 study · 34 participantsVery low
Lower salt intake vs usual or high salt intake
MAP Duration: up to 12 weeks · patients with diabetes with or without CKD
1 finding from 1 review
- Altered dietary salt intake for preventing diabetic kidney disease and its progression 2023 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 59 participantsLow
Lower salt intake vs usual or high salt intake
Systolic blood pressure · patients with diabetes with or without CKD
1 finding from 1 review
- Altered dietary salt intake for preventing diabetic kidney disease and its progression 2023 · Cochrane Headline outcomes onlyno estimate extracted5 studies · 108 participantsLow
Lower salt intake vs usual or high salt intake
Diastolic blood pressure · patients with diabetes with or without CKD
1 finding from 1 review
- Altered dietary salt intake for preventing diabetic kidney disease and its progression 2023 · Cochrane Headline outcomes onlyno estimate extracted5 studies · 108 participantsLow
Prebiotic vs another prebiotic
Distension · people with CKD
1 finding from 1 review
- Synbiotics, prebiotics and probiotics for people with chronic kidney disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 24 participantsVery low
Calcineurin inhibitors ± oral steroids vs oral steroids alone
Adverse events: hypertension · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in adverse effects: hypertension compared with oral steroids alone (low certainty).
1 finding from 1 review
- Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes onlyRR 0.86 [0.23, 3.2]3 studies · 219 participantsLow
Cyclosporin vs different comparators
Adverse events: hypertension · adults with FSGS
1 finding from 1 review
- Interventions for focal segmental glomerulosclerosis in adults 2022 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 187 participantsVery low
Early vs standard initiation of kidney replacement therapy (KRT)
Adverse events: hypotension · AKI
Early leads to higher adverse events: hypotension compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
1 finding from 1 review
- Timing of kidney replacement therapy initiation for acute kidney injury 2022 · Cochrane Headline outcomes onlyRR 1.54 [1.29, 1.85]5 studies · 3864 participantsHigh
Lower salt intake vs higher salt intake
Reduction in antihypertensive dose · people with CKD
It is very uncertain whether lower salt intake changes reduction in antihypertensive dose compared with higher salt intake (very low certainty).
1 finding from 1 review
- Altered dietary salt intake for people with chronic kidney disease 2021 · Cochrane Headline outcomes onlyRR 2.45 [0.98, 6.08]7 studies · 664 participantsVery low
Lower salt intake vs higher salt intake
Symptomatic hypotension · people with CKD
Lower salt intake probably leads to higher symptomatic hypotension compared with higher salt intake (moderate certainty).
1 finding from 1 review
- Altered dietary salt intake for people with chronic kidney disease 2021 · Cochrane Headline outcomes onlyRR 6.7 [2.4, 18.69]6 studies · 478 participantsModerate
Heparin vs placebo
Readmissions to intensive care: all heparin · kidney transplant recipients
It is very uncertain whether heparin changes readmissions to intensive care: all heparin compared with placebo (very low certainty).
1 finding from 1 review
- Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes onlyRR 0.68 [0.12, 3.9]3 studies · 180 participantsVery low
Steroid therapy in first episode of nephrotic syndrome: five to seven months vs three months
Adverse events: hypertension · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: five to… showed no clear difference in adverse events: hypertension compared with three months (moderate certainty).
1 finding from 1 review
- RR 1.11 [0.71, 1.74]6 studies · 752 participantsModerate
Steroid therapy in first episode of nephrotic syndrome: 3 months or more vs 2 months of therapy
Adverse events: hypertension · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: hypertension compared with 2 months of therapy (moderate certainty).
1 finding from 1 review
- RR 1.78 [0.55, 5.73]7 studies · 548 participantsModerate
Mycophenolate mofetil vs cyclosporin
Adverse events: hypertension · SSNS in children
Mycophenolate mofetil showed no clear difference in adverse effects: hypertension compared with cyclosporin (low certainty).
1 finding from 1 review
- Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes onlyRR 0.3 [0.09, 1.07]3 studies · 144 participantsLow
Alkylating agents vs cyclosporin
Adverse events: hypertension · SSNS in children
It is very uncertain whether alkylating agents changes adverse effects: hypertension compared with cyclosporin (very low certainty).
1 finding from 1 review
- Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes onlyRR 0.33 [0.01, 7.72]1 study · 40 participantsVery low
Dihydropyridine vs non‐dihydropyridine calcium channel blockers
Intradialytic hypotension · people with CKD requiring dialysis
The review found no eligible studies for this question.
1 finding from 1 review
- Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Dihydropyridine calcium channel blockers vs placebo or control
Intradialytic hypotension · people with CKD requiring dialysis
Dihydropyridine calcium channel blockers showed no clear difference in intradialytic hypotension compared with placebo/control (low certainty).
1 finding from 1 review
- Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes onlyRR 0.54 [0.25, 1.15]2 studies · 287 participantsLow
CHRONIC: ACEi or ARB vs placebo
Hypotension (ARB; withdrawn from study) · heart failure with chronic kidney disease
It is very uncertain whether CHRONIC: ACEi or ARB changes hypotension (ARB; withdrawn from study) compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes onlyRR 2.6 [1.12, 6.07]1 study · 332 participantsVery low
CHRONIC: Beta‐blockers vs placebo
Hypotension · heart failure with chronic kidney disease
It is very uncertain whether CHRONIC: Beta‐blockers changes hypotension compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes onlyRR 5.11 [0.25, 106.15]1 study · 704 participantsVery low